Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Isabel Munevar"'
Autor:
Diana Carolina Sierra-Díaz, Adrien Morel, Dora Janeth Fonseca-Mendoza, Nora Contreras Bravo, Nicolas Molano-Gonzalez, Mariana Borras, Isabel Munevar, Mauricio Lema, Henry Idrobo, Daniela Trujillo, Norma Serrano, Ana Isabel Orduz, Diego Lopera, Jaime González, Gustavo Rojas, Paula Londono-De Los Ríos, Ray Manneh, Rodrigo Cabrera, Wilson Rubiano, Jairo de la Peña, María Catalina Quintero, William Mantilla, Carlos M. Restrepo
Publikováno v:
Human Genomics, Vol 18, Iss 1, Pp 1-14 (2024)
Abstract Background In Colombia and worldwide, breast cancer (BC) is the most frequently diagnosed neoplasia and the leading cause of death from cancer among women. Studies predominantly involve hereditary and familial cases, demonstrating a gap in t
Externí odkaz:
https://doaj.org/article/94dcc3407c7a4832a2bb89dbf14cae2d
Autor:
William Mantilla, Maríafernanda Gonzalez, Sebastián Rojas, Mariana Borras-Osorio, Nicolas Molano-Gonzalez, Diego Moran, Joaquín Hernando Guerra, Oscar Romero, Isabel Munevar
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSEBreast cancer (BC) is the most frequent neoplasm in women in Colombia and is associated with a higher mortality rate than in other countries and regions. Neoadjuvant chemotherapy (NACT) has become a standard treatment in locally advanced BC an
Externí odkaz:
https://doaj.org/article/d7ce038f240b485db91e674d7f900616
Autor:
Claudia Lucía Sossa, Virginia Abello, Humberto Martinez, Jheremy Enrique Reyes Castellanos, Guillermo Enrique Quintero Vega, William Armando Mantilla Duran, Kenny Galvez, Rigoberto Gómez Gutierrez, Henry Idrobo Quintero, Carmen Rosales, Mario Ernesto Correa Correa, Paola Andrea Guerrero Burbano, Lina Maria Gaviria Jaramillo, Isabel Munevar, Yazmin Borjas, Luis Antonio Salazar, Angela María Peña, Manuel Rosales, David Martinez-Cuadrón, Pau Montesinos, Manuel Sanz
Publikováno v:
HemaSphere, Vol 7, p e4961422 (2023)
Externí odkaz:
https://doaj.org/article/04b0e43486574cbeaf8c6aff60d9ca15
Autor:
William Mantilla, Maria-Fernanda Gonzalez, Sebastian Rojas, Mariana Borras-Osorio, Nicolas Molano-Gonzalez, Joaquin Guerra, Isabel Munevar, Diego Moran
Publikováno v:
Cancer Research. 83:P4-06
Introduction Breast cancer (BC) is the most frequent neoplasm in Colombia, with mortality rate increasing in past decade. The expected 5-year overall survival (OS) is < 80%, being the Latin American country with the worst prognosis. 2 factors related
Autor:
Mauricio Luján, Mauricio Lema, Beatriz Preciado, Camila Lema, Jorge Egurrola, Andrés Cardona, Diego González, William Mantilla, Luis Pino, Gustavo Rojas, Diego Gómez, Isabel Munevar, Raimundo Manneh, Ray Manneh, José Lobatón, Esteban Calle, Mariana Borras, Iván Triana, Paula Londoño, Sandra Aruachán, Mateo Pineda, Diego Morán
Publikováno v:
Journal of Investigative Medicine. 71:502-510
Nivolumab is a human programmed death receptor-1 blocking antibody, used as treatment option in patients with advanced non-small-cell lung cancer (NSCLC). We assessed the nivolumab efficacy in terms of survival and response to treatment as second-lin
Autor:
Diana Carolina Sierra-Díaz, Adrien Morel, Dora Janeth Fonseca, Nora Contreras, Mariana Angulo-Aguado, Valentina Balaguera, Kevin Llinás-Caballero, Isabel Munevar, Mariana Borras, Mauricio Lema, Henry Idrobo, Daniela Trujillo, Norma Serrano, Ana Isabel Orduz, Diego Lopera, Jaime Gonzalez, Gustavo Rojas, Paula Londoño, Ray Manneh, Catalina Quintero, Paul Laissue, Rodrigo Cabrera, Carlos M Restrepo, William Mantilla
Publikováno v:
Cancer Research. 82:P3-07
Introduction In Colombia Breast cancer (BC), is the most frequent and has the highest mortality rate among all types of cancer. There are few studies of the genomic profile in unselected affected population by BC in Colombia. Some of these studies ha
Autor:
Virginia Abello, William Armando Mantilla, Henry Idrobo, Claudia Lucia Sossa, Luis Antonio Salazar, Angela Pena, Juan Manuel Herrera, Paola Guerrero, Daniel Espinosa, Guillermo Enrique Quintero-Vega, Isabel Munevar, Kenny Galvez, Alicia Henao, Rigoberto Gómez, Jose Domingo Saavedra, Lina María Gaviria, Mónica Osuna, María Victoria Mateos
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e405-e413
Multiple Myeloma (MM) is a plasma cell derived clonal disorder that represents around 1% of all newly diagnosed neoplasms. Limited data regarding MM treatment in Latin America is available, and access to novel agents for a substantial portion of the
Autor:
Carmen Alcalá, Sandra Aruachan, Giovanna Rivas, Ivan Camilo Triana, Néstor Llinás, Alicia Quiroga, Ray Manneh Kopp, Javier Cuello, Paola Andrea Pinilla, Paola Jiménez, Henry Idrobo, Fernando Contreras, Ricardo Brugés, William Mantilla, José Fernando Lobatón, Juliana Bogoya, Héctor González, Jesús Insuasty, Jorge Miguel Otero, Javier Segovia, Carlos Vargas, Aylen Vanessa Ospina, Manuel González, Milton Lombana, Javier F. Pacheco, Isabel Munevar, Henry Vargas, Juan Ortiz, Laura Bernal, Angela Barrero, Pedro M. Ramos, Gilberto Lopes, Andrea Russi, Luis Pino, Daniel Andres Santa
Publikováno v:
The Oncologist
Repositorio U. El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Repositorio U. El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Introduction The ACHOCC‐19 study was performed to characterize COVID‐19 infection in a Colombian oncological population. Methodology Analytical cohort study of patients with cancer and COVID‐19 infection in Colombia. From April 1 to October 31,
Autor:
Aylen Vanessa Ospina Serrano, Ricardo Elias Bruges Maya, Pedro Ramos, Ivan Triana, Sandra Aruachan, Alicia Quiroga, Giovanna Patricia Rivas Tafurt, Isabel Munevar, William Mantilla, Ana Cristina Avendaño, Hector Alirio Gonzalez Florez, Paola Jimenez, Javier orlando Pacheco, Paola Pinilla, Ray Manneh Kopp, Juan David Ortiz Diaz, Jesus Insuasty, Marcela Alcala, Angela Barrero, Guillermo Sanchez-Vanegas
Publikováno v:
Journal of Clinical Oncology. 40:e18721-e18721
e18721 Background: In our experience during the first year of development of ACHOC-C19 study, we observed 26% mortality in patients with cancer and COVID 19 infection. The impact of vaccination was not evaluated prior to the implementation of this st
Autor:
Mauricio Lujan, Mauricio Lema, Beatriz Preciado, Camila Lema, Jorge Egurrola, Andres Felipe Cardona Zorrilla, Diego Mauricio Gonzalez, William Armando Mantilla, Luis Pino, Gustavo Rojas, Diego Andres Gomez-Abreo, Isabel Munevar, Raimundo Manneh, Ray Manneh Kopp, Jose F. Lobaton, Esteban Calle, Mariana Borras, Ivan Camilo Triana, Mateo Pineda, Diego Moran Ortio
Publikováno v:
Journal of Clinical Oncology. 40:e21094-e21094
e21094 Background: Nivolumab is a human programmed death receptor-1 (PD-1) blocking antibody, used as treatment option in patients with advanced non-small cell lung cancer (NSCLC). We assessed the nivolumab efficacy in terms of survival and response